Caseware UK (AP4) 2024.0.164 2024.0.164 2025-01-312025-01-310falsetrue2024-01-253No description of principal activityfalseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 15442526 2024-01-24 15442526 2024-01-25 2025-01-31 15442526 2023-01-25 2024-01-24 15442526 2025-01-31 15442526 c:Director1 2024-01-25 2025-01-31 15442526 d:OfficeEquipment 2024-01-25 2025-01-31 15442526 d:OfficeEquipment 2025-01-31 15442526 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-01-25 2025-01-31 15442526 d:CurrentFinancialInstruments 2025-01-31 15442526 d:CurrentFinancialInstruments d:WithinOneYear 2025-01-31 15442526 d:ShareCapital 2025-01-31 15442526 d:RetainedEarningsAccumulatedLosses 2025-01-31 15442526 c:OrdinaryShareClass1 2024-01-25 2025-01-31 15442526 c:OrdinaryShareClass1 2025-01-31 15442526 c:OrdinaryShareClass2 2024-01-25 2025-01-31 15442526 c:OrdinaryShareClass2 2025-01-31 15442526 c:OrdinaryShareClass3 2024-01-25 2025-01-31 15442526 c:OrdinaryShareClass3 2025-01-31 15442526 c:OrdinaryShareClass4 2024-01-25 2025-01-31 15442526 c:OrdinaryShareClass4 2025-01-31 15442526 c:FRS102 2024-01-25 2025-01-31 15442526 c:AuditExempt-NoAccountantsReport 2024-01-25 2025-01-31 15442526 c:FullAccounts 2024-01-25 2025-01-31 15442526 c:PrivateLimitedCompanyLtd 2024-01-25 2025-01-31 15442526 e:PoundSterling 2024-01-25 2025-01-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 15442526










LEAFRY PHARMA MANAGEMENT LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 31 JANUARY 2025

 
LEAFRY PHARMA MANAGEMENT LTD
REGISTERED NUMBER: 15442526

STATEMENT OF FINANCIAL POSITION
AS AT 31 JANUARY 2025

2025
Note
£

Fixed assets
  

Tangible assets
 4 
799

  
799

Current assets
  

Debtors: amounts falling due within one year
 5 
371

Cash at bank and in hand
 6 
6,907

  
7,278

Creditors: amounts falling due within one year
 7 
(4,833)

Net current assets
  
 
 
2,445

Total assets less current liabilities
  
3,244

  

Net assets
  
3,244


Capital and reserves
  

Called up share capital 
 8 
5

Profit and loss account
  
3,239

  
3,244


Page 1

 
LEAFRY PHARMA MANAGEMENT LTD
REGISTERED NUMBER: 15442526
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 JANUARY 2025

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 17 March 2025.




S J Farley
Director

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
LEAFRY PHARMA MANAGEMENT LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2025

1.Accounting policies

 
1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
1.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
1.3

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

 
1.4

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.


Page 3

 
LEAFRY PHARMA MANAGEMENT LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2025

1.Accounting policies (continued)

 
1.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment
-
33%
straight-line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
1.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
1.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
1.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
1.9

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 4

 
LEAFRY PHARMA MANAGEMENT LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2025

2.


General information

Leafry Pharma Management Ltd is a private company, limited by shares and incorporated in England.
Its registered number is: 15442526
Its registered office is:
4 Salisbury Close
Stotfold
Bedfordshire
SG5 4FL


3.


Employees

The average monthly number of employees, including directors, during the period was 3.


4.


Tangible fixed assets





Office equipment

£



Cost or valuation


Additions
1,198



At 31 January 2025

1,198



Depreciation


Charge for the period on owned assets
399



At 31 January 2025

399



Net book value



At 31 January 2025
799


5.


Debtors

2025
£


Other debtors
371

371


Page 5

 
LEAFRY PHARMA MANAGEMENT LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2025

6.


Cash and cash equivalents

2025
£

Cash at bank and in hand
6,907

6,907



7.


Creditors: Amounts falling due within one year

2025
£

Corporation tax
2,441

Other creditors
952

Accruals and deferred income
1,440

4,833



8.


Share capital

2025
£
Allotted, called up and fully paid


2 Ordinary shares of £1.00 each
2
1 Ordinary B share of £1.00
1
1 Ordinary C share of £1.00
1
1 Ordinary D share of £1.00
1

5


During the period the Company issued two Ordinary £1 shares, one Ordinary £1 B share, one Ordinary £1 C share and one Ordinary £1 D share for a total considration of £5


9.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company  to the fund and amounted to £22,500.

 
Page 6